Cargando…
Targeting mTOR for the treatment of AML. New agents and new directions
Despite recent advances in the field, the treatment of patients with acute myeloid leukemia (AML) remains challenging and difficult. Although chemotherapeutic agents induce remissions in a large number of patients, many of them eventually relapse and die. A major goal for the development of new appr...
Autores principales: | Altman, Jessica K., Sassano, Antonella, Platanias, Leonidas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248202/ https://www.ncbi.nlm.nih.gov/pubmed/21680954 |
Ejemplares similares
-
SYK Regulates mTOR Signaling in AML
por: Carnevale, Julia, et al.
Publicado: (2013) -
Dendrite pathology and neurodegeneration: focus on mTOR
por: Di Polo, Adriana
Publicado: (2015) -
Roles of mTOR in Diabetic Kidney Disease
por: Yasuda-Yamahara, Mako, et al.
Publicado: (2021) -
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
por: Colamonici, Marco, et al.
Publicado: (2015) -
Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
por: Eckerdt, Frank, et al.
Publicado: (2019)